In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spiros Development Corp. II Inc.

Division of Perrigo Co. PLC

Latest From Spiros Development Corp. II Inc.

Opportunism Knocks

In this era of pharmaceutical industry consolidation, large pharmaceutical companies, and in particular the newly-merged, taking stock of their increasing bulk, have been heard to say that they will drop products in development that don't have the potential to achieve at least $500 million in revenues. Big pharmas are also looking more critically at their small products already on the market. For these large companies, small products could prove to be a distraction that diverts resources away from potential blockbusters, the kinds of products that the companies will need to grow by 15% a year going forward. In theory, then, as pharmaceutical companies up-average product portfolios in favor of high-revenue producers and prune away redundant or non-strategic products in the aftermath of mergers, many more commercializable products should become available for licensing than ever before. That is the hope, anyway, of a handful of new specialty pharmaceutical companies formed to acquire on-the-market products with the aim of growing their sales through a variety of strategies. These companies avoid product development risk but bear risk of a different sort. To be successful, they must be able to continually acquire products that can grow, and not pay too much for them.
BioPharmaceutical Strategy

Holding Our Breath for Inhale

Pulmonary delivery seems a narrow base on which to build a company; but Inhale is confident that through rigorous focus, it can construct plenty of deals on it. In the meantime, all eyes are on its insulin deal with Pfizer. That deal's success or failure--for reasons that may have nothing to do with Inhale or its technology--will either bring in partners still uncertain about the delivery system or scare them off.
BioPharmaceutical Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register